MOUNTAIN VIEW, Calif., Feb. 15, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that management is planning to present at two investor conferences in March 2011. The conferences and presentation dates and times are as follows:
- Raymond James 32nd Annual Institutional Investors Conference on Wednesday, March 9, 2011, at 8:05 a.m. Eastern time at the JW Marriott Orlando Grande Lakes, Orlando, FL
- Roth 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011, at 12:00 p.m. Pacific time at The Ritz Carlton, Laguna Niguel, CA
Live webcasts of the presentations will be available on the company's website at www.conceptus.com. When accessing the webcasts through the Conceptus site, select "Investors" then select "Events and Presentations." The archived replay for the Raymond James 32nd Annual Institutional Investors Conference will be available for a period of 7 days. The archived replay for the Roth 23rd Annual OC Growth Stock Conference will be available for a period of 30 days.
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.
Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with nearly 500,000 women worldwide having undergone the Essure procedure.
About Conceptus, Inc.
Conceptus, Inc. is a leader in the design, development, and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East. The Company also promotes the GYNECARE THERMACHOICE® Uterine Balloon Therapy System by ETHICON™ Women's Health & Urology, a division of Ethicon, Inc., in U.S. OB/GYN physician offices.
Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.
The Conceptus, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7961
© 2011 Conceptus, Inc -- All rights reserved. Conceptus, Essure and Your Family is Complete. Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc.
CC-2630 15FEB11F